News, views and contacts from the global Pharmaceutical industry

Takeda: White Papers

Make An Enquiry


New Post-Hoc Analyses Extend Understanding of the Efficacy and Safety of Lurasidone in the Treatment of Schizophrenia Tuesday, April 07, 2015 Takeda Pharmaceuticals International and Sunovion Pharmaceuticals has announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda (lurasidone) in patients...


Multiple Scientific Posters Supporting the Efficacy, Safety and Tolerability of Once-daily Latuda® (lurasidone) are Presented at the 27th ECNP Congress Thursday, November 06, 2014 Takeda and Sunovion have presented new evidence supporting the use of Latuda® (lurasidone), an atypical antipsychotic treatment for adults with schizophrenia, during multiple poster sessions...